BioProcess International’s Post

At Wheeler Bio, Inc., we are bringing the hub-and-spoke model to the CDMO space to solve longstanding obstacles for early biotechs! Innovators are faced with ample challenges from the start due to limited resources, high burn rates, and an uncertain funding environment. Due to this, it becomes difficult to manage multiple vendors, tech transfers, and high upfront costs. The Wheeler hub-and-spoke model connects the best in their respective fields into one streamlined offering, ensuring your program receives the specialized knowledge and experience it requires while integrating into a one-stop-shop from Discovery to IND. Follow the link below to learn more about how we are changing the CDMO landscape to cater to early stage biotechs or feel free to reach out to info@wheelerbio.com to chat with us! #Biotech #Biologics #Pharma #CMC #StartUp

ICYMI: Dan Smithey, PhD and four experienced c-level executives from leading development, technology, manufacturing and bioprocess partner organizations sat down with Kurt Nielsen to discuss the innovations needed to get your molecule to market in these challenging times. Why do we need to innovate? ""As molecules get more complex, they require more technology and innovation to be absorbed or delivered properly. Ultimately, drug development partners have to adopt new technologies to help our clients be successful. If we aren't technology aggressive, we simply won't be able to deliver successful medicines."", Dan Smithey, CEO Listen to the entire panel discussion here:https://hubs.li/Q02k-hdK0 #drugdevelopment #drugmanufacturing #partner #cdmo

For any of my network working in life Sciences, take the 50 seconds to watch the video below. And if you have a whole 7 minutes there is a lot more insights in the longer video https://lnkd.in/envCUxA7

Really interesting discussion to hear in case you missed it!

💡 In pharma and biotech, technology transfer can be slow and costly. But with digital platforms, we can revolutionize tech transfer, shaping a better healthcare system. 🌐💊 Let's embrace innovation to accelerate progress and improve patient outcomes. Watch video here 👉 https://lnkd.in/dhg-kcvz #Pharma #Biotech #DigitalTransformation

💡 In pharma and biotech, technology transfer can be slow and costly. But with digital platforms, we can revolutionize tech transfer, shaping a better healthcare system. 🌐💊 Let's embrace innovation to accelerate progress and improve patient outcomes. Watch video here 👉 https://lnkd.in/dFzCnYh5 #Pharma #Biotech #DigitalTransformation

💡 In pharma and biotech, technology transfer can be slow and costly. But with digital platforms, we can revolutionize tech transfer, shaping a better healthcare system. 🌐💊 Let's embrace innovation to accelerate progress and improve patient outcomes. Watch video here 👉 http://spr.ly/6045kOHud #Pharma #Biotech #DigitalTransformation

Pharma companies today have to deal with many challenges: 💊 Rising drug discovery costs 💊 Pressure to accelerate timelines 💊 Ever-evolving regulatory requirements 💊 Supply chain uncertainties And more. Enter: Lab transformation. ⚗️ Our latest #PharmaIndustry research shows that organizations leading in the creation of their future-ready “next-gen” labs gain multiple advantages, including accelerated time to market, error reduction, and improved approval rates. How are these leaders creating more agile and sustainable labs? And how can your organization create and scale its own #LabOfTheFuture? Grab your copy of our report to find out 👉 https://lnkd.in/dDrP3tEx #DigitalLab #FutureLab #LifeSciences #Innovation

I am pleased to share the publication of our research article titled "Deep integration of low-cost liquid handling robots in an industrial pharmaceutical development environment" in SLAS Technology. In this study, we explore the integration of the Opentrons OT-2 liquid handling robot with Roche's in-house workflow orchestration software, AutoLab. Our findings demonstrate how this cost-efficient and flexible automation solution can enhance experimental efficiency in pharmaceutical research. We have included the code used for the integration with the paper, which we hope will facilitate future integrations for others in the community! 🔗 Read the full article and access the code here: https://lnkd.in/g46sx435 I would like to extend my gratitude to my co-authors Anton Thieme, Sean Renwick, Michaela Marschmann, Pedro Ivo Guimarães, and Susanne Weissenborn, as well as the extended AutoLab team for their invaluable contributions. #PharmaceuticalResearch #LabAutomation #FAIRData #Digitalization #Innovation #Opentrons #AutoLab

📢 Join AustinPx for an upcoming webinar to explore the growing role of amorphous solid dispersions (#ASD) in drug development, driven by the increase in poorly soluble molecules. With next-gen technologies like KinetiSol™ setting new benchmarks for scalability and performance, this session will dive into overcoming common scale-up challenges. The featured speakers will share their experiences with technology transfers, best practices for scale-up, and how to enhance the manufacturability of ASDs. Gain insights into improving tech transfer processes and ensuring successful commercialization. ➡️ REGISTER HERE: https://buff.ly/3XBy5dO 🌟 Featured speakers: Justin Keen TJ Higley #DrugDevelopment #PharmaceuticalManufacturing #DrugManufacturing #AmorphousSolidDispersions #CommercialManufacturing #APIFormulationDevelopment